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Background
T-VEC is an oncolytic immunotherapy derived from
herpes simplex virus type-1 designed to selectively repli-
cate within tumors and to produce GM-CSF to enhance
systemic antitumor immune responses. OPTiM, a rando-
mized Phase III trial of T-VEC vs GM-CSF in patients
with unresected melanoma with regional or distant metas-
tases met the primary objective of an improvement in dur-
able response rate (response lasting continuously for ≥6
months) with T-VEC versus GM-CSF (16% vs 2%, respec-
tively; P<0.001). Most common adverse events with
T-VEC were fatigue, chills, and pyrexia. No ≥grade 3
adverse events occurred in ≥3% of patients in either arm
(Andtbacka et al., J Clin Oncol 2013,32[suppl]:LBA9008).
At the primary analysis (PA) of secondary OS endpoint,
with median follow-up of 44 (range, 32-59) months and
189 events in the T-VEC arm and 101 events in the GM-
CSF arm, median (95%CI) OS was 23.3 (19.5-29.6) months
for T-VEC and 18.9 (16.0-23.7) months for GM-CSF
(hazard ratio [HR]=0.79; 95%CI = 0.62-1.00; P = 0.051)
(Kaufman et al., J Clin Oncol 2014,32[suppl]:9008a). A-
planned analysis of OS at 3 years from the last randomiza-
tion is presented here.
Methods
Eligible patients were ≥18 years old; had ECOG perfor-
mance status (PS) ≤1; unresectable melanoma stage
IIIB/C/IV; injectable cutaneous, subcutaneous (SC) or
nodal lesions; LDH≤1.5X upper limit of normal; ≤3 visc-
eral lesions (excluding lung), none>3 cm. Patients were
randomized 2:1 to intralesional T-VEC (initially ≤4 mL
x106 pfu/mL, then after 3 wks, ≤4 mL x108 pfu/mL
q2w) or SC GM-CSF (125 µg/m2qd × 14 ds q4w).
Results
Of 436 patients in the intent-to-treat analysis, 295 (68%)
patients received T-VEC and 141 (32%) patients received
GM-CSF; 57% were men; median age 63 yrs. At time of
the final OS analysis with median follow-up of 49 months
[range, 37-63], only 1 additional event occurred (T-VEC
arm). Median (95%CI) OS was 23.3 months (95%CI =
19.5-29.6) for T-VEC and 18.9 months (16.0-23.8) for GM-
CSF; HR = 0.80 (95%CI = 0.62-1.01), P = 0.06 (descriptive).
Five-year survival for the T-VEC arm was 33.4% (95%CI =
27.7-39.2). T-VEC effect on OS was most pronounced in
patients with stage IIIB/C/IVM1a melanoma (HR = 0.57;
95%CI = 0.41-0.81, P = 0.001 [descriptive]) and in patients
with treatment-naive disease (HR = 0.52; 95%CI =
0.36-0.75, P < 0.001 [descriptive]).
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Conclusions
With >4 years of median follow-up for survival, a persistent
relevant OS effect was demonstrated with further follow-
up. Long-term follow-up continues in the registry trial
(NCT02173171). T-VEC represents a novel potential ther-
apy for patients with regionally and distantly metastatic
melanoma.
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